scholarly journals B-cell non-Hodgkin lymphoma linked to Coxiella burnetii

Blood ◽  
2016 ◽  
Vol 127 (1) ◽  
pp. 113-121 ◽  
Author(s):  
Cléa Melenotte ◽  
Matthieu Million ◽  
Gilles Audoly ◽  
Audrey Gorse ◽  
Hervé Dutronc ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Coxiella Burnetii ◽  
Q Fever ◽  
Non Hodgkin Lymphoma ◽  
Increased Risk ◽  
Key Points

Key PointsCoxiella burnetii is associated with an increased risk of lymphoma; its presence in the tumor microenvironment may favor lymphomagenesis. Lymphoma has to be considered in patients with Q fever and lymphoid disorders, especially those with persistent focalized infections.

scholarly journals Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma

Blood ◽  
2018 ◽  
Vol 131 (21) ◽  
pp. 2345-2356 ◽  
Author(s):  
Elena Battistello ◽  
Natalya Katanayeva ◽  
Elie Dheilly ◽  
Daniele Tavernari ◽  
Maria C. Donaldson ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Molecular Subtypes ◽  
Src Kinase ◽  
Cell Receptor ◽  
B Cell Receptor ◽  
Oncogenic Signaling ◽  
Kinase Inhibition ◽  
Non Hodgkin Lymphoma ◽  
Key Points

Key Points Inhibition of BTK in patients who are resistant to ibrutinib changes signaling tumor dependencies and promotes MYC upregulation. Multitarget inhibition of LYN, FYN, and BLK is therapeutically effective in patients with DLBCL independent of their molecular subtypes.

scholarly journals Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma

Blood ◽  
2011 ◽  
Vol 117 (2) ◽  
pp. 585-590 ◽  
Author(s):  
Yingtai Chen ◽  
Tongzhang Zheng ◽  
Qing Lan ◽  
Francine Foss ◽  
Christopher Kim ◽  
...  
Keyword(s):  
Body Mass Index ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Body Mass ◽  
Significant Interaction ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Lymphocytic Leukemia ◽  
Non Hodgkin Lymphoma ◽  
Increased Risk

Abstract We conducted a population-based, case-control study in Connecticut women to test the hypothesis that genetic variations in Th1 and Th2 cytokine genes modify the relationship between body mass index (BMI) and risk of non-Hodgkin lymphoma (NHL). Compared with those with BMI less than 25 kg/m2, women with BMI more than or equal to 25 kg/m2 had 50% to 90% increased risk of NHL among women who carried IFNGR2 (rs9808753) AA, IL5 (rs2069812) CT/TT, IL7R (rs1494555) AA, and TNF (rs1799724) CC genotypes, but no increased risk among women with IFNGR2 AG/GG, IL5 CC, IL7R AG/GG, and TNF CT/TT genotypes. A significant interaction with BMI was only observed for IFNGR2 (rs9808753 Pforinteraction = .034) and IL7R (rs1494555 Pforinteraction = .016) for NHL overall; IL7R (rs1494555 Pforinteraction = .016) and TNF (1799724 Pforinteraction = .031) for B-cell lymphoma; and IL5 (rs2069812 Pforinteraction = .034) for T-cell lymphoma. After stratification by common B-cell lymphoma subtypes, a significant interaction was observed for IFNGR2 (rs9808753 Pforinteraction = .006), IL13 (rs20541 Pforinteraction = .019), and IL7R (rs1494555 Pforinteraction = .012) for marginal zone B-cell lymphoma; IL7R (rs1494555 Pforinteraction = .017) for small lymphocytic lymphoma/chronic lymphocytic leukemia; and IL12A (rs568408 Pforinteraction = .013) and TNF (1799724 Pforinteraction = .04) for follicular lymphoma. The results suggest that common genetic variation in Th1/Th2 pathway genes may modify the association between BMI and NHL risk.

scholarly journals A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma

Blood ◽  
2013 ◽  
Vol 122 (6) ◽  
pp. 951-957 ◽  
Author(s):  
Mark P. Purdue ◽  
Jonathan N. Hofmann ◽  
Troy J. Kemp ◽  
Anil K. Chaturvedi ◽  
Qing Lan ◽  
...  
Keyword(s):  
Prospective Study ◽  
Hodgkin Lymphoma ◽  
Blood Collection ◽  
Inflammation Markers ◽  
Non Hodgkin Lymphoma ◽  
Increased Risk ◽  
Key Points ◽  
A Prospective Study

Key Points Elevated levels of BCA-1, sTNFR2, and sVEGFR2 are associated with increased risk for NHL several years after blood collection.

scholarly journals Late Health Outcomes After Contemporary Lymphome Malin de Burkitt Therapy for Mature B-Cell Non-Hodgkin Lymphoma: A Report From the Childhood Cancer Survivor Study

2019 ◽  
Vol 37 (28) ◽  
pp. 2556-2570 ◽  
Author(s):  
Matthew J. Ehrhardt ◽  
Yan Chen ◽  
John T. Sandlund ◽  
Elizabeth C. Bluhm ◽  
Robert J. Hayashi ◽  
...  
Keyword(s):  
Health Status ◽  
Health Outcomes ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Chronic Health Conditions ◽  
Health Conditions ◽  
Socioeconomic Outcomes ◽  
Non Hodgkin Lymphoma ◽  
Increased Risk ◽  
Childhood Cancer Survivor Study

PURPOSE The widely used, risk-based Lymphome Malin de Burkitt (LMB) chemotherapy regimen has improved survival rates for children with mature B-cell non-Hodgkin lymphoma (NHL); however, associated late effects remain understudied. We assessed late health outcomes after LMB treatment in the Childhood Cancer Survivor Study. PATIENTS AND METHODS Multivariable regression models compared chronic health conditions, health status, and socioeconomic and neurocognitive outcomes between survivors of NHL treated with the LMB regimen (n = 126), survivors of NHL treated with non-LMB regimens (n = 444), and siblings (n = 1,029). RESULTS LMB survivors were a median age of 10.2 years (range, 2.5 to 20.5 years) at diagnosis and 24.0 years (range, 10.3 to 35.3 years) at evaluation. Compared with siblings, LMB survivors were at increased risk for adverse health outcomes. However, survivors of NHL treated with LMB and non-LMB regimens did not differ with regard to risk of having any chronic health conditions, impaired health status, neurocognitive deficits, or poorer socioeconomic outcomes. Increased risk for the following specific neurologic conditions was observed in LMB survivors compared with non-LMB survivors: epilepsy (relative risk [RR], 15.2; 95% CI, 3.1 to 73.4); balance problems (RR, 8.9; 95% CI, 2.3 to 34.8); tremors (RR, 7.5; 95% CI, 1.9 to 29.9); weakness in legs (RR, 8.1; 95% CI, 2.5 to 26.4); severe headaches (RR, 3.2; 95% CI, 1.6 to 6.3); and prolonged arm, leg, or back pain (RR, 4.0; 95% CI, 2.2 to 7.1). The survivors from the group C LMB risk group (n = 50) were at the highest risk for these conditions; however, except for worse functional status (odds ratio, 2.7; 95% CI, 1.2 to 5.8), they were not at increased risk for other adverse health status or socioeconomic outcomes compared with non-LMB survivors. CONCLUSION Survivors treated with LMB and non-LMB regimens are largely comparable in late health outcomes except for excess neurotoxicity among LMB survivors. These data inform treatment efforts seeking to optimize disease control while minimizing toxicity.

scholarly journals Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis

2018 ◽  
Vol 2 (12) ◽  
pp. 1429-1438 ◽  
Author(s):  
Samuel Yamshon ◽  
Paul J. Christos ◽  
Michelle Demetres ◽  
Hoda Hammad ◽  
John P. Leonard ◽  
...  
Keyword(s):  
Systematic Review ◽  
Multiple Myeloma ◽  
Venous Thromboembolism ◽  
Venous Thrombosis ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Meta Analysis ◽  
Non Hodgkin Lymphoma ◽  
Key Points

Key Points Lenalidomide is associated with increased venous thrombosis in patients with B-cell NHL, similar to multiple myeloma.

scholarly journals Genetic Variation in B-Cell–Activating Factor Is Associated with an Increased Risk of Developing B-Cell Non–Hodgkin Lymphoma

2009 ◽  
Vol 69 (10) ◽  
pp. 4217-4224 ◽  
Author(s):  
Anne J. Novak ◽  
Susan L. Slager ◽  
Zachary S. Fredericksen ◽  
Alice H. Wang ◽  
Michelle M. Manske ◽  
...  
Keyword(s):  
Genetic Variation ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
B Cell Activating Factor ◽  
Increased Risk

scholarly journals Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma

Blood ◽  
2014 ◽  
Vol 124 (8) ◽  
pp. 1259-1265 ◽  
Author(s):  
Paul M. Barr ◽  
Thomas P. Miller ◽  
Jonathan W. Friedberg ◽  
Derick R. Peterson ◽  
Andrea M. Baran ◽  
...  
Keyword(s):  
Gene Expression ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Phase 2 ◽  
Related Gene ◽  
Cellular Redox ◽  
Non Hodgkin Lymphoma ◽  
Phase 2 Study ◽  
Key Points

Key Points Clinical responsiveness to imexon represents the first demonstration of efficacy with modulating cellular redox in B-cell NHL. Antioxidant-related gene expression predicted for response to imexon.

scholarly journals HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma

Blood ◽  
2015 ◽  
Vol 125 (11) ◽  
pp. 1768-1771 ◽  
Author(s):  
Roberta Zappasodi ◽  
Giusi Ruggiero ◽  
Carla Guarnotta ◽  
Monica Tortoreto ◽  
Cristina Tringali ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Therapeutic Target ◽  
Valuable Alternative ◽  
Non Hodgkin Lymphoma ◽  
Key Points

Key Points In human aggressive B-NHLs, HSPH1 favors c-Myc and Bcl-6 expression, and its inhibition provides significant antilymphoma activity. HSPH1 is expressed in function of Bcl-6 and c-Myc and constitutes a valuable alternative lymphoma therapeutic target of aggressive B-NHLs.

Hepatitis B Infection Is Associated with an Increased Risk of Non-Hodgkin Lymphoma: A Meta-Analysis.

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 2658-2658
Author(s):  
Samir Dalia ◽  
Julio Chavez ◽  
Jorge J Castillo ◽  
Lubomir Sokol
Keyword(s):  
Hepatitis B ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Cell Lymphoma ◽  
Meta Analysis ◽  
B Cell Lymphoma ◽  
Lymphocytic Leukemia ◽  
Hbv Infection ◽  
Non Hodgkin Lymphoma ◽  
Increased Risk

Abstract Abstract 2658 Introduction: Hepatitis B virus (HBV) infection is a major global public health problem with the World Health Organization reporting about 350 million people with chronic HBV infection with the highest rates seen in Asia and Africa. Multiple studies have attempted to show an association between HBV infection and non-Hodgkin lymphoma (NHL) but have had conflicting results. Objectives: The primary aim of our study was to evaluate the association between HBV infection and the incidence of NHL using a meta-analysis of epidemiological studies. Secondary aims were to evaluate such association in NHL subtypes and by geographical region. Methods: A MEDLINE and Google Scholar search through July 2012 were undertaken using (Hepatitis B or hepatitis) AND (lymphoma OR “risk of lymphoma” OR “hematologic malignancies” OR “lymphoproliferative disorders” OR “non Hodgkin lymphoma”). Only epidemiological studies reporting on HBV infection and NHL were included. Hepatitis B status confirmation method was recorded. Meta-analyses were performed for NHL in general, by NHL subtypes, and according to geographical region. The outcome was calculated as odds ratio (OR). The random effects model (REM) was used to calculate the outcome. Heterogeneity was assessed by the I2 statistic. Publication bias was assessed by the trim-and-fill analysis. Literature search and data gathering were performed independently by at least 2 of the investigators. All graphs and calculations were obtained using Comprehensive Meta-Analysis version 2 (Biostat, Englewood, NJ). Results: Our search yielded 21 studies; 17 case-control studies accounted for 38,630 cases and 1,659,449 controls, and 4 prospective cohort studies accounted for 1,258 cases indentified in a cohort of over 2.4 million individuals. HBV infection was confirmed by seropositivity in 81% of studies (n=17). HBV infection patients had an OR 2.30 (95% CI 1.87–2.84; p=<0.001) of developing NHL. OR was significant in patients from Asian countries (OR 2.31, 95% CI 1.87–2.86, p<0.001) and in patients from American/European/Australian countries (OR 2.58, 95% CI 1.43–4.62, p=0.002). In subgroup analysis, HBV infection patients had an OR 2.10 (95% CI 1.27–3.49, p=0.004) of developing diffuse large B-cell lymphoma (DLBCL). In patients from Asian countries, HBV infection was associated with an increased risk of DLBCL (OR 3.05, 95% CI 1.86–5.00, p<0.001); an association was not found in patients from Europe or Australian studies. Patients with HBV infection had increased risk to develop follicular lymphoma (OR 1.966, 95% CI 1.211–3.193, p<0.001) and B-cell lymphomas (OR 2.67, 95% CI 2.08–3.43, p<0.001). Patients with HBV infection did not have increased risk to develop chronic lymphocytic leukemia/small cell lymphoma (OR 1.58, 95% CI 0.70–3.62, p=0.27) or T-cell lymphomas (OR 1.37, 95% CI 0.95–1.98, p=0.091). Conclusions: The results of this meta-analysis suggest a positive association between HBV infection and NHL, DLBCL, follicular lymphoma, and B-cell lymphoma. There was no association between HBV infection and chronic lymphocytic leukemia/small cell lymphoma or T-cell lymphomas. Future research is needed to better understand molecular mechanisms responsible for lymphomagenesis in patients with chronic HBV infection. Disclosures: No relevant conflicts of interest to declare.

scholarly journals A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma

Blood ◽  
2009 ◽  
Vol 114 (13) ◽  
pp. 2730-2732 ◽  
Author(s):  
Mark P. Purdue ◽  
Qing Lan ◽  
Otoniel Martinez-Maza ◽  
Martin M. Oken ◽  
William Hocking ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Ovarian Cancer Screening ◽  
Hiv Patients ◽  
Cell Stimulation ◽  
Non Hodgkin Lymphoma ◽  
Soluble Cd30 ◽  
Increased Risk ◽  
A Prospective Study ◽  
Nested Case Control

Abstract Prediagnostic serum concentration of soluble CD30 (sCD30), a marker for chronic B-cell stimulation, has been associated with increased risk of developing AIDS-related non-Hodgkin lymphoma (NHL) in a recent study of HIV+ patients. To investigate among healthy persons whether serum sCD30 is associated with NHL risk, we carried out a nested case-control study within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. There was a strong dose-response relationship between prediagnostic sCD30 concentration and NHL risk among 234 cases and 234 individually matched controls (odds ratio [95% confidence interval] for second, third, and fourth quartiles vs first quartile: 1.4 [0.8-2.6], 2.2 [1.2-4.1], 4.1 [2.2-7.8]; Ptrend < .001), which persisted among cases diagnosed 6 to 10 years after providing a blood sample. Given that a similar relationship has been observed among HIV+ patients, our findings suggest that chronic B-cell stimulation may be an important mechanism involved in B-cell lymphomagenesis among severely immunocompromised and healthy populations alike.

Sign in / Sign up

Export Citation Format

Share Document